

## Special Issue

# Molecular Insights into Osteosarcoma

### Message from the Guest Editors

The quote "Cellular pathology is not an end if one cannot see any alteration in the cell. Chemistry brings the clarification of living processes nearer than does anatomy. Each anatomical change must have been preceded by a chemical one." as stated by Rudolf Virchow (Coper, H., Herken, H., 1963. Dtsch. Med. Wochenschr. 88, 2025–2036). Osteosarcoma is a comparatively painstaking topic for many paediatricians, paediatric surgeons, and paediatric pathologists, because despite progress in numerous paediatric malignancies, the outcomes of the affected individuals are still quite poor.

We would be very grateful to gather basic science articles and clinical reports for this Special Issue, which concentrates on the molecular insights of osteosarcoma. As Virchow stated, a chemical change is the basis of what the pathologists sees under the microscope and the physician can assess clinically. We hope to receive several contributions that may attract the attention of funders and charities in promoting more research in the relatively poorly explored field of pre-cancerous bone histology.

---

### Guest Editors

Dr. Fan Shen

Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB T6G 2B7, Canada

Prof. Dr. Consolato M. Sergi

Department of Laboratory Medicine & Pathology, Division of Anatomical Pathology, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, ON K1H 8L1, Canada

---

### Deadline for manuscript submissions

closed (30 September 2024)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/160609](https://mdpi.com/si/160609)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).